List of Excipients in Branded Drug TETRACAINE HYDROCHLORIDE

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alcon Laboratories Inc	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	0065-0741	ACETIC ACID
Alcon Laboratories Inc	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	0065-0741	SODIUM ACETATE
Alcon Laboratories Inc	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	0065-0741	SODIUM CHLORIDE
Alcon Laboratories Inc	TETRACAINE HYDROCHLORIDE	tetracaine hydrochloride	0065-0741	WATER

Generic Drugs Containing TETRACAINE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Somerset Therapeutics LLC	tetracaine hydrochloride	70069-596	BORIC ACID
Somerset Therapeutics LLC	tetracaine hydrochloride	70069-596	CHLOROBUTANOL
Somerset Therapeutics LLC	tetracaine hydrochloride	70069-596	EDETATE DISODIUM
Somerset Therapeutics LLC	tetracaine hydrochloride	70069-596	HYDROCHLORIC ACID

What are the Most Frequently-Used Excipients in TETRACAINE HYDROCHLORIDE?

# Of NDCs	Excipient
1	BORIC ACID
1	CHLOROBUTANOL
1	EDETATE DISODIUM
1	HYDROCHLORIC ACID

Last updated: September 25, 2026

ecutive summary: Tetracaine hydrochloride is an established ester local anesthetic with limited opportunity in the active ingredient itself and greater commercial potential in formulation, packaging, delivery, and lifecycle management. The strongest excipient strategies address aqueous instability, ophthalmic tolerability, preservative exposure, viscosity, sterility, and rapid onset. High-value opportunities include preservative-free ophthalmic unit doses, stabilized multidose drops, metered topical systems, compounded-to-commercial gel or cream platforms, and differentiated sterile injectable presentations. Core composition-of-matter exclusivity is not a meaningful barrier because tetracaine is an old generic active ingredient. Competitive protection is more likely to arise from formulation, device, manufacturing, and method-of-use claims.

Tetracaine Hydrochloride Excipient Strategy and Commercial Opportunities

What is tetracaine hydrochloride used for?

Tetracaine hydrochloride is a potent ester-type local anesthetic used to produce surface or regional anesthesia. Commercial and clinical applications include ophthalmic anesthesia, topical anesthesia of skin or mucous membranes, and injectable local or spinal anesthesia, depending on the formulation and regulatory approval.

Tetracaine hydrochloride is the water-soluble hydrochloride salt of tetracaine. The salt supports aqueous formulation but does not eliminate the principal development issues:

• Hydrolytic degradation associated with the ester functionality.
• Sensitivity to pH, temperature, light, and storage conditions.
• Potential irritation from preservatives and high excipient concentrations.
• Need for sterile manufacturing in ophthalmic and injectable products.
• Narrow margin between effective local anesthesia and systemic toxicity.
• Limited suitability for some sustained-release or high-dose delivery systems because of potency and toxicity.

Typical strength calculations are straightforward:

Label strength	Tetracaine hydrochloride concentration
0.5% ophthalmic solution	5 mg/mL
1% solution	10 mg/mL
2% topical product	20 mg/g or mL, depending on dosage form
4% topical product	40 mg/g or mL, depending on dosage form

The commercial significance of the strength is substantial. A higher concentration may support faster or stronger local anesthesia but increases toxicity, irritation, manufacturing controls, and regulatory scrutiny.

Which dosage forms offer the best excipient opportunities?

The strongest opportunities are in ophthalmic solutions, topical gels and creams, sterile injectables, and unit-dose delivery systems.

Dosage form	Primary excipient challenge	Commercial opportunity
Ophthalmic solution	Sterility, preservative toxicity, comfort, stability	Preservative-free unit dose or low-preservative multidose system
Ophthalmic gel	Residence time, visual blurring, dose uniformity	Controlled-contact anesthesia with reduced administration frequency
Topical gel	Tetracaine crystallization, viscosity, skin penetration	Fast-onset, metered-dose, non-greasy gel
Topical cream	Uniform drug distribution and sensory properties	Dermatology, procedural, and mucosal anesthesia
Injectable solution	Sterility, pH, particulate control, stability	Preservative-free presentations and ready-to-use containers
Injectable depot	Release control and systemic toxicity	Higher-risk, specialized regional anesthesia applications
Combination product	Compatibility with other anesthetics or antiseptics	Differentiated procedure-specific products

Ophthalmic and topical products generally present the most practical development path. Injectable depot systems may offer stronger differentiation but have higher clinical, toxicological, and regulatory risk.

What excipients are commonly used with tetracaine hydrochloride?

Public product labeling and established local-anesthetic formulation practice identify several recurring excipient classes. Exact excipient selection must be validated against the intended route, concentration, container, sterilization process, and preservative strategy.

Ophthalmic solution excipients

Tetracaine hydrochloride ophthalmic solutions commonly use:

• Purified water or water for injection.
• Sodium chloride for isotonicity.
• Boric acid or borate systems for buffering and tonicity adjustment.
• Hydrochloric acid or sodium hydroxide for pH adjustment.
• Benzalkonium chloride or another ophthalmic preservative in multidose products.

The formulation objective is not simply to maximize chemical stability. It must also minimize ocular discomfort, corneal epithelial toxicity, precipitation, and visual disturbance.

Benzalkonium chloride is commercially familiar and widely used in ophthalmic products, but chronic or repeated exposure can damage the ocular surface in susceptible patients. A preservative-free unit-dose product can therefore create a clinically meaningful differentiation point, especially for repeated procedural use or patients with ocular-surface disease. The preservative-free approach requires single-dose packaging, validated microbial controls, and a higher packaging cost.

Borate and phosphate buffers require route-specific evaluation. Buffer capacity can affect comfort and degradation behavior. A formulation with a low buffer capacity may provide better tolerability while still maintaining acceptable pH during shelf life.

Topical gel and cream excipients

Topical products may use:

• Carbomers.
• Hydroxypropyl methylcellulose.
• Hydroxyethyl cellulose.
• Poloxamers.
• Polyethylene glycols.
• Propylene glycol.
• Glycerin.
• Purified water.
• Mineral oil or petrolatum in cream or ointment systems.
• Surfactants and emulsifiers.
• Preservatives such as phenoxyethanol or parabens, where justified.

Carbomer gels can increase residence time and improve application control, but excessive viscosity may delay drug release and produce poor spreadability. Poloxamer systems can support thermoresponsive gelation, although the value of this approach depends on whether the product is intended for skin, mucosa, or the eye.

Propylene glycol and polyethylene glycol may improve solvent capacity and penetration. They can also cause stinging or irritation, particularly on damaged skin or mucosal tissue. A formulation that relies heavily on cosolvents may therefore have a weaker tolerability profile even if it provides rapid release.

For topical products, the commercial target is usually a balance among onset, residence time, spreadability, sensory properties, and drug delivery. Excipient selection should be linked to a measurable product claim such as faster onset, longer duration, lower application volume, or reduced reapplication frequency.

How should an excipient strategy address tetracaine hydrochloride stability?

Tetracaine hydrochloride requires a stability program centered on hydrolysis, pH, temperature, light, and container compatibility.

pH control

The formulation pH affects both chemical stability and the fraction of unionized tetracaine available to cross lipid membranes. A higher pH may improve membrane permeation by increasing the unionized fraction, but it can also increase irritation and alter degradation kinetics. The optimum pH is therefore product-specific rather than universal.

Development should assess:

• Assay and degradation products across a pH range.
• Precipitation risk after pH adjustment.
• Ocular or dermal irritation.
• Onset and duration of anesthesia.
• Compatibility with the proposed container closure.
• Stability after opening or repeated dosing.

The target pH should be supported by a balance of stability, tolerability, and performance data rather than selected solely from theoretical ionization behavior.

Buffer and tonicity systems

Sodium chloride is a practical tonicity agent for aqueous solutions. Borate systems may support both buffering and tonicity, but the concentrations should remain within route-specific tolerability limits.

For ophthalmic products, osmolality and pH are major quality attributes. Hypertonic or strongly buffered products may cause burning and reflex tearing, which can reduce delivered dose and patient acceptance.

Antioxidants and chelators

Antioxidants and chelating agents should not be added routinely. Their use requires evidence that oxidative degradation or trace-metal catalysis is a material pathway. Candidate systems may include sodium metabisulfite, disodium edetate, or other compatible stabilizers, but each can create new risks involving hypersensitivity, tolerability, regulatory acceptability, or interaction with packaging.

A low-excipient formulation with appropriate pH, oxygen control, and container selection may be preferable to a heavily stabilized product.

Container closure and light protection

Container selection can materially affect shelf life. Relevant options include:

• Low-density polyethylene ophthalmic bottles.
• Unit-dose blow-fill-seal containers.
• Glass vials or ampoules.
• Laminated tubes for topical gels.
• Metered-dose pumps.
• Airless containers.

The development program should evaluate sorption, leachables, extractables, oxygen transmission, moisture transmission, light exposure, and dose delivery over the full labeled shelf life. Tetracaine hydrochloride products may also require protection from excessive heat and light based on product-specific stability data.

What preservative strategy is commercially attractive?

Preservative-free packaging is the clearest differentiated opportunity in ophthalmic tetracaine hydrochloride.

Preservative-free unit-dose products

A preservative-free product can address:

• Ocular-surface toxicity concerns.
• Use in patients receiving repeated ophthalmic procedures.
• Operating-room or procedure-room dosing.
• Reduced cross-contamination risk.
• Institutional preference for single-use sterile products.

The tradeoff is higher packaging cost, more complex filling operations, greater packaging volume, and potential waste from unused product. The business case is strongest where the product is used in a controlled procedure rather than chronic self-administration.

Preserved multidose products

Multidose bottles have lower per-dose packaging costs and are familiar to providers. The main risks are preservative exposure, microbial contamination after opening, and competitive commoditization.

A differentiated multidose product could use a preservative-minimizing delivery system, such as a one-way valve or metered pump. These systems can support a reduced-preservative claim if validated through antimicrobial effectiveness, in-use stability, and microbiological challenge testing.

What formulation patents could protect tetracaine hydrochloride products?

For an old generic active ingredient, the most defensible patent positions usually involve the product architecture rather than tetracaine hydrochloride itself.

Potential claim categories include:

1. A defined tetracaine concentration and pH range.
2. A specific buffer and tonicity system.
3. A preservative-free unit-dose ophthalmic composition.
4. A low-preservative multidose container.
5. A gel with defined viscosity, release, or residence-time characteristics.
6. A formulation with reduced degradation products after storage.
7. A sterile container-closure configuration.
8. A method of producing a stable tetracaine hydrochloride solution.
9. A metered-dose topical delivery system.
10. A combination with another anesthetic, antiseptic, vasoconstrictor, or penetration enhancer.

Patent strength depends on more than listing known excipients. A patent application is more credible when it includes comparative data showing an unexpected result, such as:

• Higher stability than conventional formulations.
• Lower ocular irritation at equivalent anesthetic exposure.
• Faster onset at a lower concentration.
• Longer duration without increasing total dose.
• Improved content uniformity in a high-viscosity gel.
• Lower preservative burden with equivalent microbial protection.
• Better delivery consistency across container life.

Broad claims covering tetracaine hydrochloride with common excipients may face substantial novelty and obviousness challenges. Narrow claims tied to a specific composition, manufacturing parameter, device, or measured performance attribute are more likely to provide meaningful protection.

When does tetracaine hydrochloride lose exclusivity?

Tetracaine hydrochloride has been used clinically for decades. The active ingredient is therefore outside any practical new-molecule exclusivity period. Core composition-of-matter protection is not a meaningful commercial barrier for current development.

The relevant exclusivity questions concern individual products:

• Whether an approved product has unexpired formulation or method-of-use patents.
• Whether an NDA or 505(b)(2) product has regulatory exclusivity.
• Whether a listed patent appears in the FDA Orange Book.
• Whether a generic applicant must submit a Paragraph IV certification.
• Whether the proposed product uses a different route, dosage form, or clinical indication.

For most conventional tetracaine hydrochloride generic products, the principal competitive barriers are regulatory compliance, sterile manufacturing, product quality, supply reliability, and distribution rather than patent exclusivity.

What is the Orange Book and Paragraph IV risk for tetracaine products?

The FDA Orange Book identifies approved drug products, therapeutic equivalence evaluations, and certain patents and exclusivity information for listed products. A tetracaine hydrochloride developer must assess the specific reference product rather than assume that the active ingredient is unprotected.

Paragraph IV risk is generally limited for a standard generic when:

• The reference product has no relevant unexpired listed patents.
• The proposed formulation does not infringe an active formulation patent.
• The product uses the same route and dosage form.
• The applicant can satisfy quality, sterility, and bioequivalence or applicable performance requirements.

Risk increases for a 505(b)(2) product that introduces:

• A new dosage form.
• A new route of administration.
• A new concentration.
• A new combination.
• A new delivery device.
• A new clinical use.
• A pharmacokinetic or clinical advantage supported by new studies.

A 505(b)(2) strategy may create a more defensible commercial position than an ordinary ANDA, but it also increases development cost and the possibility of patent litigation.

Which companies are challenging tetracaine hydrochloride products?

Tetracaine hydrochloride is primarily a generic-market product. Competition is more likely to arise among generic manufacturers, specialty ophthalmic companies, hospital-product suppliers, compounding pharmacies, and developers of alternative local anesthetics than through high-profile originator litigation.

Potential competitors include products containing:

• Proparacaine hydrochloride.
• Lidocaine hydrochloride.
• Benzocaine.
• Bupivacaine hydrochloride.
• Ropivacaine hydrochloride.
• Combination topical anesthetic products.

The relevant competitive comparison is usually clinical and operational:

Attribute	Tetracaine hydrochloride	Proparacaine hydrochloride	Lidocaine
Chemical class	Ester	Ester	Amide
Common ophthalmic use	Surface anesthesia	Surface anesthesia	Less common as standard ophthalmic drop
Key formulation issue	Stability and tolerability	Stability and tolerability	Route-specific formulation and systemic exposure
Differentiation route	Preservative-free delivery, gel, device	Similar ophthalmic improvements	Topical, injectable, liposomal, or combination systems
Biosimilar relevance	None	None	None

There is no biosimilar pathway for tetracaine hydrochloride because it is a small-molecule drug, not a biologic. Competition proceeds through ANDA, 505(b)(2), or other applicable small-molecule regulatory routes.

What FDA regulatory pathway applies to new tetracaine formulations?

The pathway depends on the degree of similarity to an approved reference product.

ANDA

An ANDA is appropriate when the proposed product can demonstrate sameness or the required equivalence to an approved reference product. This route is most relevant for conventional tetracaine hydrochloride ophthalmic solutions, injectables, or topical products where the dosage form, route, strength, and performance are sufficiently aligned with the reference.

505(b)(2)

A 505(b)(2) application may be appropriate for:

• A new gel or emulsion.
• A new strength.
• A novel topical delivery system.
• A new route or site of administration.
• A combination product.
• A product requiring clinical studies to support a new use or delivery advantage.

A 505(b)(2) product can support commercial differentiation but must establish the safety and effectiveness of the proposed changes.

Drug-device combination

A metered pump, applicator, or preservative-free delivery system may create combination-product requirements. Device performance, dose accuracy, container closure, sterility, and human factors become part of the regulatory package.

What manufacturing and intellectual-property barriers exist?

The most material manufacturing barriers are sterile processing, content uniformity, degradation control, container compatibility, and supply-chain reliability.

Sterile manufacturing

Ophthalmic and injectable products require validated aseptic processing or terminal sterilization where feasible. Tetracaine hydrochloride stability may constrain sterilization conditions. A developer must establish:

• Sterility assurance.
• Endotoxin controls for applicable products.
• Particulate limits.
• Filter compatibility.
• Hold-time stability.
• Fill-volume accuracy.
• Container-closure integrity.

Topical manufacturing

Topical gels and creams require robust control of:

• Drug distribution.
• Particle size and crystallization.
• Viscosity.
• Mixing order.
• Homogeneity.
• Microbial limits.
• Preservative effectiveness.
• In-use stability.

These process controls can create practical barriers even where patent protection is weak.

Supply-chain considerations

Tetracaine hydrochloride is an established active pharmaceutical ingredient, so API availability is generally less differentiated than finished-dose manufacturing. Commercial risk can arise from API-source qualification, impurity profiles, residual solvents, nitrosamine assessment where applicable, and dependence on a small number of qualified sterile fill-finish sites.

What licensing deals are commercially realistic?

Large licensing transactions for tetracaine hydrochloride itself are unlikely because the molecule is old and broadly available. More realistic transactions involve:

• Rights to a proprietary ophthalmic container.
• Licensing of a preservative-free multidose system.
• A topical gel platform.
• A sterile fill-finish arrangement.
• Regional commercialization rights.
• A combination product with a new clinical indication.
• Contract development and manufacturing partnerships.

The licensable asset should therefore be the formulation, device, manufacturing process, or regulatory package. A partner is more likely to value a product that has demonstrated stability, a clear regulatory pathway, defensible patent claims, and access to a specialty channel such as ophthalmology, dermatology, dentistry, or ambulatory surgery.

What generic launch scenarios exist for tetracaine hydrochloride?

Three launch scenarios are commercially relevant.

Standard generic launch

A conventional ophthalmic solution or injectable product competes on price, availability, quality, and supply reliability. Margins are likely to be exposed to multiple suppliers unless the product has a supply constraint or institutional contract advantage.

Premium generic launch

A preservative-free unit-dose product, improved bottle, or ready-to-use sterile presentation can support a higher price. The premium must be justified by reduced waste, procedural convenience, improved tolerability, or procurement requirements.

Specialty 505(b)(2) launch

A gel, metered topical system, combination product, or new-use formulation can create stronger differentiation. This pathway requires more development work but may support method-of-use, formulation, and device protection.

Revenue exposure depends primarily on the channel. Hospital and procedure-room products may have lower unit volumes but higher value per dose. Retail ophthalmic products may have larger distribution potential but face stronger generic substitution and price pressure.

How strong is the patent estate for tetracaine hydrochloride?

The patent estate for the active ingredient is weak from a lifecycle-management perspective because tetracaine hydrochloride is an established generic molecule. The strongest potential rights are product-specific.

Protection category	Expected strategic value
Composition of matter	Low for new development
Conventional solution formulation	Low to moderate
Preservative-free unit-dose system	Moderate
Novel container or metered device	Moderate to high
Topical gel with demonstrated performance	Moderate
Manufacturing process	Moderate if difficult to design around
New method of use	Moderate to high if clinically differentiated
Combination product	Moderate to high
Trade secret process controls	Useful operationally, limited exclusionary scope

Patent durability improves when formulation claims are paired with device claims, manufacturing claims, and regulatory exclusivity. No single excipient is likely to create a strong moat. The commercial defense should be built around a complete product system.

Key Takeaways

• Tetracaine hydrochloride has no meaningful new-molecule exclusivity opportunity.
• The best commercial prospects are formulation and delivery improvements.
• Preservative-free ophthalmic unit-dose products offer the clearest differentiation.
• Multidose products may benefit from low-preservative or preservative-minimizing delivery systems.
• Topical gels can compete through residence time, onset, spreadability, and sensory performance.
• pH, hydrolysis, tonicity, sterility, and container compatibility are central development variables.
• Conventional excipient combinations are unlikely to support broad, durable patent claims without comparative performance data.
• ANDA development is most appropriate for conventional products; 505(b)(2) is more suitable for novel dosage forms, devices, combinations, or uses.
• Biosimilar competition is not relevant because tetracaine hydrochloride is a small-molecule drug.
• The strongest commercial assets are likely to be a validated formulation, a proprietary delivery system, a reliable sterile manufacturing process, and a focused specialty-market strategy.

FAQs About Tetracaine Hydrochloride Formulation and Commercialization

Can tetracaine hydrochloride be formulated without benzalkonium chloride?

Yes. A preservative-free ophthalmic product can use single-dose packaging or a validated preservative-minimizing multidose system. The product must meet sterility, container-closure, in-use stability, and microbiological requirements.

Is tetracaine hydrochloride suitable for a sustained-release formulation?

It may be suitable for selected topical or local-delivery systems, but sustained release increases exposure-control and toxicity requirements. The development case is stronger where prolonged local anesthesia reduces procedures or reapplication.

Which excipient is best for a tetracaine hydrochloride gel?

No universal excipient is best. Carbomers, cellulose derivatives, and poloxamers can each be appropriate depending on the target site, viscosity, release rate, residence time, and tolerability profile.

Can a tetracaine hydrochloride formulation receive new patent protection?

Yes, but protection is more likely for a defined formulation, device, manufacturing process, or method of use than for tetracaine hydrochloride itself. Comparative stability, tolerability, release, or delivery data materially improve patent position.

Is tetracaine hydrochloride a biosimilar opportunity?

No. Tetracaine hydrochloride is a small-molecule active ingredient. Commercial development uses small-molecule pathways such as ANDA or 505(b)(2), not the biosimilar pathway.

References

1. DailyMed. (n.d.). Tetracaine hydrochloride ophthalmic solution prescribing information. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (2017). Approved drug products with therapeutic equivalence evaluations, 43rd edition. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (2022). ANDA submissions: Content and format of an abbreviated new drug application. https://www.fda.gov/drugs

4. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). https://www.fda.gov/drugs

5. U.S. Pharmacopeia. (2024). General chapter <771> ophthalmic products. United States Pharmacopeial Convention.

6. U.S. Pharmacopeia. (2024). General chapter <797> pharmaceutical compounding: Sterile preparations. United States Pharmacopeial Convention.